{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"youtube":4,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06097832\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NEXICART-2","nct_id":"NCT06097832","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nexicart-2-nct06097832. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"NEXICART-2","arms":[{"description":"The dose escalation phase will include the following doses:\n\nCohort 1 - 150×10\\^6 CAR-positive (CAR+) T cells (3 patients) Cohort 2 - 450×10\\^6 CAR-positive (CAR+) T cells (3 patients) The dose expansion phase will then proceed.","label":"NXC-201 CAR-T","type":"EXPERIMENTAL"}],"collaborators":["Immix Biopharma, Inc."],"completion_date":{"date":"2039-01","type":"ESTIMATED"},"conditions":["Light Chain (AL) Amyloidosis"],"enrollment":{"count":45,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"NXC-201 CAR-T","type":"BIOLOGICAL"}],"last_update":"2026-07-14","lead_sponsor":"Nexcella Inc.","official_title":"Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants With Treatment-Related Adverse Events","timeFrame":"24 months"},{"measure":"Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0","timeFrame":"24 months"},{"measure":"To confirm the maximum tolerated dose (MTD)","timeFrame":"24 months"},{"measure":"To confirm the recommended phase 2 dose (RP2D)","timeFrame":"24 months"}],"references":[{"citation":"Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637.","pmid":"36107221","type":"BACKGROUND"},{"citation":"Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628.","pmid":"36200421","type":"BACKGROUND"},{"citation":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22.","pmid":"23091105","type":"BACKGROUND"},{"citation":"Al Haddad N, Brailovski E, Dela-Pena J, Cook M, Rosenzweig M, Jolie Landau H. BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma. EJHaem. 2026 Jun 16;7(3):e70329. doi: 10.1002/jha2.70329. eCollection 2026 Jun.","pmid":"42312318","type":"DERIVED"}],"start_date":{"date":"2024-06-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis","url":"https://clinicaltrials.gov/study/NCT06097832"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nexicart-2-nct06097832"}